Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Proteome-wide base editor screens to assess phosphorylation site functionality in immunosenescence

Award Number: R01CA279795
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2029

Group Awards By:

View Award Description

Proteome-wide base editor screens to assess phosphorylation site functionality in immunosenescence - Abstract We often depict signaling pathways by a dozen or so landmark phosphorylation events that culminate in the transcription of a gene or induction of a phenotype. In reality, a cascade of hundreds to thousands of phosphorylation sites create dynamic biochemical networks that orchestrate essentially every cellular process from expression of transcriptional programs and cell proliferation to migration and cytotoxic effector functions. T cell signaling is an important example. Signal transduction through the T cell receptor and co-stimulatory molecules is incredibly complex and leads to important but distinct downstream effects necessary for proper immune responses to pathogens, cancer, and vaccines. As humans age, T cell signaling becomes detrimentally altered, leading to “immunosenescence” and less efficient protection from malignancies. Mass spectrometry has enabled the profiling of tens of thousands of phosphorylation sites from a diverse range of cells and tissues. Unfortunately, functionally characterizing the tens of thousands of post-translational modifications cells use to coordinate essentially all cellular and organismal processes remains a fundamental challenge in biology. Here, we propose an innovative technology that will enable the functional assessment of thousands of phosphorylation sites in high throughput. We will employ CRISPR-mediated base editors, which mutate codons in genomic DNA, coupled to phenotypic screens to probe the signaling events that lead to specific T cell stimulation-specific gene expression programs or proliferation responses. Preliminary data from our laboratory strongly suggests that we can functionally screen tens of thousands of phosphorylation sites for their contribution to NFAT or NFKB signaling in stimulated T cells. In this proposal, we will further optimize this technology to create a robust, reliable screening platform. To validate our screening technology, we will characterize a subset of phosphorylation site mutants using conventional genomic engineering methods to understand how our screening platform compares to classic approaches to study phosphorylation site function, i.e. one mutation at a time. We will also extend this approach to primary human CD8+ T cells, to show that we can uncouple the signaling events that lead to cell proliferation or expression of the activation/exhaustion marker PD1. High throughput functional screening of phosphorylation sites in primary immune cells will revolutionize the way we study signaling pathways and cellular decision making, and the way we approach drug development or adoptive cell therapies to treat cancer and a variety of human ailments associated with aging.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $559,601 )
2026	2026	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Biology Research	001	3	4/16/2026	NON-COMPETING CONTINUATION	$55,960
2026	2026	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Biology Research	000	3	1/28/2026	NON-COMPETING CONTINUATION	$503,641
														Subtotal = $559,601

Issue Date FY: 2025 ( Subtotal = $566,215 )
2025	2025	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Biology Research	001	2	9/24/2025	NON-COMPETING CONTINUATION	$56,622
2025	2025	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Biology Research	000	2	1/23/2025	NON-COMPETING CONTINUATION	$509,593
														Subtotal = $566,215

Issue Date FY: 2024 ( Subtotal = $573,738 )
2024	2024	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Biology Research	000	1	4/9/2024	NEW	$573,738
														Subtotal = $573,738

Grand Total All Awards = $1,699,554

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Proteome-wide base editor screens to assess phosphorylation site functionality in immunosenescence

Award Number: R01CA279795

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer